#PriorityReview

Latest posts tagged with #PriorityReview on Bluesky

Trending

#U.S. Foreign Policy #F1 #Chinese Grand Prix #SNL #Venezuela Baseball #AEW Collision #Six Nations #Newcastle United #Arsenal vs Everton #Trump and Epstein #U.S. Foreign Policy #F1 #Chinese Grand Prix #SNL #Venezuela Baseball #AEW Collision #Six Nations #Newcastle United #Arsenal vs Everton #Trump and Epstein

Posts tagged #PriorityReview

星良孝 Yoshitaka Hoshi

@yoshitakahoshi.bsky.social

6 hours ago

エンハーツ、HER2陽性早期乳がんの術後療法で米国FDAの優先審査に指定再発・死亡リスクを53％低減 | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見

【ENHERTU Granted Priority Review in the US for Patients with HER2-Positive Early Breast Cancer】
エンハーツ、HER2陽性早期乳がんの術後療法で米国FDAの優先審査に指定再発・死亡リスクを53％低減

stellanews.life/technology/9...

#Enhertu #BreastCancer #FDA #PriorityReview #HER2Positive #MedicalNews

0 0 0 0

星良孝 Yoshitaka Hoshi

@yoshitakahoshi.bsky.social

1 week ago

ファイザー、HYMPAVZIのsBLAがFDAに受理優先審査付与で小児・インヒビター保有血友病へ適応拡大目指す | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学技術・医療・ライフサイエンスの分野における研究 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学技術・医療・ライフサイエンスの分野における研究

U.S. FDA Accepts Pfizer’s Supplemental Biologics License Application for Priority Review of HYMPAVZI (marstacimab)

stellanews.life/technology/8...

#Hemophilia #Pfizer #FDA #HYMPAVZI #PriorityReview #ClinicalTrials

0 0 0 0

星良孝 Yoshitaka Hoshi

@yoshitakahoshi.bsky.social

1 month ago

第一三共、Dato-DXdのTNBC一次治療でFDA優先審査──TROPION-Breast02に基づく生物学的製剤一部変更承認申請が受理 | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見

第一三共、Dato-DXdのTNBC一次治療でFDA優先審査──TROPION-Breast02に基づく生物学的製剤一部変更承認申請が受理
FDA grants Priority Review for datopotamab deruxtecan in first-line TNBC based on TROPION-Breast02

stellanews.life/technology/8...

#TNBC #BreastCancer #DatoDXd #TROP2 #FDA #PriorityReview

0 0 0 0

NeurologyLive®

@neurologylive.bsky.social

1 month ago

NeurologyLive - Clinical Neurology News and Neurology Expert Insights NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

🚨 FDA Update in #Narcolepsy

The #FDA has accepted Takeda’s NDA for oveporexton (TAK-861), an oral orexin receptor 2 agonist for narcolepsy type 1 — and granted Priority Review.

🗓️ PDUFA date: Q3 2026

Read more: www.neurologylive.com/view/fda-acc...
#PriorityReview #SleepMedicine #Neurology #NT1

2 0 0 0

pharmaphorum

@pharmaphorum.bsky.social

1 month ago

Otsuka preps for July decision on centanafadine for ADHD The FDA has started a priority review of Otsuka's triple-acting drug for ADHD, setting up a decision on the first-in-class drug in July.

The #FDA has started a #priorityreview of #OtsukaPharma's triple-acting drug for attention-deficit hyperactivity disorder (#ADHD), centanafadine, setting up a decision by 24th July.

1 1 0 0

pharmaphorum

@pharmaphorum.bsky.social

3 months ago

FDA starts priority review of BeOne's Venclexta rival BeOne nears a possible FDA okay for sonrotoclax in mantle cell lymphoma, hoping to be the second BCL-2 inhibitor in the US after AbbVie's Venclexta.

The #FDA has started a #priorityreview of #BeOne Medicines' BCL2 inhibitor sonrotoclax in relapsed or refractory mantle cell #lymphoma (MCL), setting up a decision on US approval next year.

pharmaphorum.com/news/fda-sta...

0 0 0 0

Rare Disease Advisor

@rarediseaseadvisor.bsky.social

5 months ago

FDA Accepts Priority Review of BLA for Orca-T in Hematologic Malignancies The FDA accepted Priority Review of the BLA for Orca-T in several hematological malignancies, including acute lymphoblastic leukemia (ALL).

Orca Bio announced that the @fda.gov has accepted for Priority Review the Biologics License Application for Orca-T, an allogeneic T-cell immunotherapy to treat #HematologicCancers, including #ALL, #MDS, and #AML.

Learn more: https://bit.ly/3IN9jmx

#RareDisease #PriorityReview #OrcaT #Oncology

0 0 0 0

OncLive

@onclive.bsky.social

7 months ago

FDA Grants Priority Review to Liso-Cel for R/R Marginal Zone Lymphoma The FDA granted priority review to a supplemental biologics license application for lisocabtagene maraleucel in relapsed/refractory marginal zone lymphoma.

FDA Grants Priority Review to Liso-Cel for R/R Marginal Zone Lymphoma
@fda.gov #MZL #PriorityReview
www.onclive.com/view/fda-gra...

1 0 0 0

Profit Trading USA

@profittradingusa.bsky.social

9 months ago

Ascendis Pharma stock rises following FDA priority review ASND hereremove ads Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #AscendisPharma #StockMarket #FDA #PriorityReview #PharmaNews

0 0 0 0

Audrey D. Zhang

@audreydzhang.bsky.social

11 years ago

ERROR: The request could not be satisfied

Question: before we give #PriorityReview vouchers for #Ebola, is there evidence that they're effective incentives? blogs.wsj.com/pharmalot/2014/10/29/law...

0 0 0 0